DOI: 10.12890/2024_004568

An inflammatory myofibroblastic tumour presenting with limited mouth-opening, hypoesthaesia of the left chin and infraorbital area, intermittent left eye ptosis and converging strabismus

Authors

  • Imen Ben Hassine Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia
  • Wiem Romdhane Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia
  • Raouaa Belkacem Department of Oral Medicine and Oral Surgery, Sahloul University Hospital, Susa, Tunisia
  • Jihed Anoun Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia
  • Wafa Baya Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia
  • Anis Mzabi Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia
  • Fatma Ben Fredj Faculty of Medicine, University of Sousse, Susa, Tunisia; Internal Medicine Department, Sahloul University Hospital, Susa, Tunisia; Geriatric medicine and Gerontology Unit, University of Sousse, Susa, Tunisia

wiem.romdhane5@gmail.com

Keywords

Myofibroblast, neoplasm, ptosis, steroids

Abstract

An inflammatory myofibroblastic tumour (IMT) is a rare neoplasm of mesenchymal origin, defined by myofibroblastic spindle cells accompanied by inflammatory cells, lymphocytes and eosinophils. Its symptomatology depends on the involved site and tends to mimic a malignant tumour clinically and radiologically. The head and neck region accounts for 5% of all IMTs. Here, we report a case of a 35-year-old woman, with no medical history, who presented with a mouth-opening limitation of 8 mm evolving for three years and occurring six months after of a wisdom tooth extraction. She also experienced a recent occurrence of left eye ptosis and a converging strabismus. On examination, the patient had a body temperature at 37°C, with hypoesthaesia of the left chin and infraorbital area, without any other abnormality. Laboratory examinations did not reveal a biological inflammatory syndrome or rhabdomyolysis. The infectious investigations were all negative, as well as the immunological tests, in particular negative for anti-AChR and anti-MuSK antibodies. On the facial computed tomography (CT) scan, we noted an active reshuffle in the left mandible ascending branch with a thickening of the ipsilateral pterygoid muscles and the left temporal meningeal tissue. After corticosteroid therapy 0.7 mg/kg/j, we obtained an improvement in the patient’s mouth-opening, thus a biopsy of the lesion was performed under local anaesthesia, revealing IMT. The patient continued the corticosteroids therapy with a progressive tapering resulting in a marked clinical improvement of the mouth-opening limitation and her ptosis.

View the entire article

Downloads

References

  1. Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer 2021;45:100768.
  2. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 2014;46:95–104.
  3. Surabhi VR, Chua S, Patel RP, Takahashi N, Lalwani N, Prasad SR. Inflammatory myofibroblastic tumors: current update. Radiol Clin North Am 2016;54:553–563.
  4. Durham C, Clemons M, Alias A, Konduri K. Locally advanced inflammatory myofibroblastic tumor treated with targeted therapy: a case report and literature review. Cureus 2022;14:e27223.
  5. Siemion K, Reszec-Gielazyn J, Kisluk J, Roszkowiak L, Zak J, Korzynska A. What do we know about inflammatory myofibroblastic tumors? A systematic review. Adv Med Sci. 2022;67:129–138.
  6. Cantera JE, Alfaro MP, Rafart DC, Zalazar R, Muruzabal MM, Barquín PG, et al. Inflammatory myofibroblastic tumours: a pictorial review. Insights Imaging 2015;6:85–96.
  7. Kube S, Vokuhl C, Dantonello T, Scheer M, Hallmen E, Feuchtgruber S, et al. Inflammatory myofibroblastic tumors – a retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 2018;65:e27012.
  8. Zhang N, Zeng Q, Chen C, Yu J, Yan D, Xu C, et al. Clinical characteristics and prognosis of pulmonary inflammatory myofibroblastic tumor: an over 10-year retrospective analysis. Pediatr Investig 2020;4:192–197.
  9. Kansara S, Bell D, Johnson J, Zafereo M. Head and neck inflammatory pseudotumor: case series and review of the literature. Neuroradiol J. 2016;29:440–446.
  10. Carswell C, Chataway J. The successful long-term management of an intracranial inflammatory myofibroblastic tumor with corticosteroids. Clin Neurol Neurosurg 2012;114:77–79.

Published

2024-08-23

How to Cite

1.
Hassine IB, Romdhane W, Belkacem R, Anoun J, Baya W, Mzabi A, et al. An inflammatory myofibroblastic tumour presenting with limited mouth-opening, hypoesthaesia of the left chin and infraorbital area, intermittent left eye ptosis and converging strabismus. EJCRIM [Internet]. 2024 Aug. 23 [cited 2026 Nov. 3];11(9). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4568

Most read articles by the same author(s)